AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options.
Zacks·3h ago
More News
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
Zacks·5d ago
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.
Zacks·7d ago
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.
Zacks·10d ago
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
Zacks·12d ago
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
Zacks·13d ago
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?
IBRX's Anktiva fueled a 700% revenue surge in 2025, but can repeat prescriptions, global expansion and BCG shortages sustain momentum into 2026?
Zacks·13d ago
Can Merck's New Drugs & Pipeline Ease Keytruda LOE Concerns?
MRK bets on new products and a growing pipeline as Keytruda nears 2028 LOE, with $70B potential commercial opportunities projected by mid-2030s.
Zacks·14d ago
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?
IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug reliance raise questions.
Zacks·17d ago
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
RHHBY reports that giredestrant plus palbociclib misses the main PFS goal in a phase III first-line breast cancer study, though the combo shows a numerical improvement.